These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28194055)

  • 1. Treatment of Acute Promyelocytic Leukemia with Single Agent Arsenic Trioxide: Experience from a Tertiary Care Center in India.
    Udupa K; Thomas J; Udupa CB; Binu VS; Sharan P
    Indian J Hematol Blood Transfus; 2017 Mar; 33(1):45-48. PubMed ID: 28194055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.
    Mathews V; Balasubramanian P; Shaji RV; George B; Chandy M; Srivastava A
    Am J Hematol; 2002 Aug; 70(4):292-9. PubMed ID: 12210810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular remission without blood product support using all-trans retinoic acid (ATRA) induction and combined arsenic trioxide/ATRA consolidation in a Jehovah's Witness with de novo acute promyelocytic leukaemia.
    Kennedy GA; Marlton P; Cobcroft R; Gill D
    Br J Haematol; 2000 Dec; 111(4):1103-5. PubMed ID: 11167746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
    Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
    N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of children with newly diagnosed acute promyelocytic leukemia with arsenic trioxide: a single center experience.
    George B; Mathews V; Poonkuzhali B; Shaji RV; Srivastava A; Chandy M
    Leukemia; 2004 Oct; 18(10):1587-90. PubMed ID: 15356649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
    Aznab M; Rezaei M
    Hematol Oncol; 2017 Mar; 35(1):113-117. PubMed ID: 26310595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematological and molecular remission with combination chemotherapy in a patient with PLZF-RARalpha acute promyelocytic leukemia (APML).
    George B; Poonkuzhali B; Srivastava VM; Chandy M; Srivastava A
    Ann Hematol; 2005 Jun; 84(6):406-8. PubMed ID: 15592671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia.
    Soignet SL
    Oncologist; 2001; 6 Suppl 2():11-6. PubMed ID: 11331435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of Arsenic Trioxide Combined with ATRA and Chemotherapy for Relapsed Acute Promyelocytic Leukemia Patients].
    Li Y; Liu KQ; Gong BF; Wang Y; Wei H; Lin D; Liu BC; Zhou CL; Wei SN; Zhang GJ; Liu YT; Gong XY; Wang JX; Mi YC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):1-6. PubMed ID: 32027244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
    Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.
    Liang B; Zheng Z; Shi Y; Chen J; Hu X; Qian H; Shen Z; Jiang S; Yu K; Feng J
    Onco Targets Ther; 2017; 10():2305-2313. PubMed ID: 28490888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.
    Ghavamzadeh A; Alimoghaddam K; Ghaffari SH; Rostami S; Jahani M; Hosseini R; Mossavi A; Baybordi E; Khodabadeh A; Iravani M; Bahar B; Mortazavi Y; Totonchi M; Aghdami N
    Ann Oncol; 2006 Jan; 17(1):131-4. PubMed ID: 16227315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment related acute promyelocytic leukemia (t-APML) in breast cancer survivor treated with anthracycline based chemotherapy: rare case report.
    Madabhavi I; Modi G; Panchal H; Patel A; Anand A; Parikh S
    Int J Hematol Oncol Stem Cell Res; 2015 Oct; 9(4):215-7. PubMed ID: 26865933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Risk Acute Promyelocytic Leukemia - An Enigma for Hematologists: Optimizing Treatment with APML-4 Protocol.
    Kapoor J; Mirgh SP; Agrawal N; Khushoo V; Tejwani N; Singh R; Mehta P; Bhurani D; Ahmed R
    Indian J Hematol Blood Transfus; 2022 Apr; 38(2):394-402. PubMed ID: 35496975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
    Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.
    Iland HJ; Collins M; Bradstock K; Supple SG; Catalano A; Hertzberg M; Browett P; Grigg A; Firkin F; Campbell LJ; Hugman A; Reynolds J; Di Iulio J; Tiley C; Taylor K; Filshie R; Seldon M; Taper J; Szer J; Moore J; Bashford J; Seymour JF;
    Lancet Haematol; 2015 Sep; 2(9):e357-66. PubMed ID: 26685769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.